Core Insights - Quantum BioPharma Ltd. has received a clinical study report (CSR) confirming the safety and tolerability of its compound Lucid-MS in a Phase 1 trial involving healthy participants [1][3][4] - Lucid-MS is a first-in-class neuroprotective compound aimed at treating multiple sclerosis (MS) and has demonstrated the ability to prevent demyelination in preclinical models [2][5] - The company is preparing to advance the clinical development of Lucid-MS towards efficacy trials in MS patients following the positive CSR results [4][5] Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with a lead compound, Lucid-MS, in its portfolio [5] - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and has a royalty agreement that includes 7% of sales until reaching $250 million, after which the royalty will drop to 3% [5] - Quantum BioPharma also maintains strategic investments through its subsidiary, FSD Strategic Investments Inc., which involves loans secured by residential or commercial properties [5]